However, patients with astrocytoma, IDH-mutant with CDKN2A/B-HD have shorter survival (expected median OS: approximately 3 years) which corresponds to WHO CNS grade 4 [19]. This evidence concerns the gene CDKN2A and astrocytoma (excluding glioblastoma).